Literature DB >> 28364941

Exploring new packaging and delivery options for the immunization supply chain.

Darin Zehrung1, Courtney Jarrahian2, Birgitte Giersing3, Debra Kristensen4.   

Abstract

A variety of vaccine packaging and delivery technologies may benefit the immunization supply chain. These include alternative primary packaging, such as blow-fill-seal polymer containers, and novel delivery technologies, such intradermal delivery devices, microarray patches, and sublingual formulations of vaccines, and others in development. The potential timeline to availability of these technologies varies and depends on their stage of development and the type of data necessary to achieve licensure. Some new delivery devices are anticipated to be introduced in 2017, such as intradermal devices for delivery of inactivated poliovirus vaccine to stretch vaccine supplies due to a supply limitation. Other new technologies requiring vaccine reformulation, such as microarray patches and sublingual vaccines, may become available in the long term (2021 and beyond). Development of many new technologies requires partnership between vaccine and technology manufacturers and identification of the applicable regulatory pathway. Interaction with public-sector stakeholders early on (through engagement with forums such as the World Health Organization's Immunization Practices Advisory Committee Delivery Technologies Working Group) is important to ensure suitability for immunization program use. Key considerations for programmatic suitability of a new vaccine, packaging, and delivery device include cold chain volume, costs, and health impact.
Copyright © 2017 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Cold chain; Delivery device; Immunization supply chain; Intradermal injections; Packaging; Sublingual administration

Mesh:

Substances:

Year:  2017        PMID: 28364941     DOI: 10.1016/j.vaccine.2016.11.095

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  5 in total

1.  Biocompatible near-infrared quantum dots delivered to the skin by microneedle patches record vaccination.

Authors:  Kevin J McHugh; Lihong Jing; Sean Y Severt; Mache Cruz; Morteza Sarmadi; Hapuarachchige Surangi N Jayawardena; Collin F Perkinson; Fridrik Larusson; Sviatlana Rose; Stephanie Tomasic; Tyler Graf; Stephany Y Tzeng; James L Sugarman; Daniel Vlasic; Matthew Peters; Nels Peterson; Lowell Wood; Wen Tang; Jihyeon Yeom; Joe Collins; Philip A Welkhoff; Ari Karchin; Megan Tse; Mingyuan Gao; Moungi G Bawendi; Robert Langer; Ana Jaklenec
Journal:  Sci Transl Med       Date:  2019-12-18       Impact factor: 17.956

2.  Enabling emergency mass vaccination: Innovations in manufacturing and administration during a pandemic.

Authors:  Divya Hosangadi; Kelsey Lane Warmbrod; Elena K Martin; Amesh Adalja; Anita Cicero; Thomas Inglesby; Crystal Watson; Matthew Watson; Nancy Connell
Journal:  Vaccine       Date:  2020-04-20       Impact factor: 3.641

3.  Vaccine innovation prioritisation strategy: Findings from three country-stakeholder consultations on vaccine product innovations.

Authors:  Mercy Mvundura; Collrane Frivold; Anna Janik Osborne; Priyanka Soni; Joanie Robertson; Sandeep Kumar; Jacqueline Anena; Abdoulaye Gueye; Marion Menozzi-Arnaud; Birgitte Giersing; Anna-Lea Kahn; Tiziana Scarna; Debra Kristensen
Journal:  Vaccine       Date:  2021-08-16       Impact factor: 3.641

4.  A method for estimating the impact of new vaccine technologies on vaccination coverage rates.

Authors:  Ben Davis; Michael Krautmann; Pascale R Leroueil
Journal:  PLoS One       Date:  2022-02-10       Impact factor: 3.240

5.  Two decades of vaccine innovations for global public good: Report of the Developing Countries' Vaccine Manufacturers Network 20th meeting, 21-23 october 2019, Rio de Janeiro, Brazil.

Authors:  Sonia Pagliusi; Maureen Dennehy; Akira Homma
Journal:  Vaccine       Date:  2020-06-10       Impact factor: 3.641

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.